POSTERS & ABSTRACTS

2018

September 30-October 3, 2018
Preclinical Pharmacokinetic and Pharmacodynamic Characterization of AB680, a Small-Molecule CD73 Inhibitor for Cancer Immunotherapy. Tan JBL, Chen J, Ginn E, Ashok D, Anderson AE, Banuelos J, Zhang K, Pham A, Park T, Chen A, Zhao X, Jin L, Lawson KV, Jeffreys J, Kalisiak J, Leleti MR, Walters MJ, and Powers JP. CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; New York, New York; abstract No. A157.

View Poster

September 30-October 3, 2018
Preclinical characterization of AB154, a fully humanized a-TIGIT antibody, for use in combination therapies Anderson AE, Becker A, Yin F, Singh H, Zhao X, Seitz L, Stanton R, Walker NPC, Tan J. CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; New York, New York; abstract No. A124.

View Poster

September 30-October 3, 2018
AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression. DiRenzo D, Piovesan D, Tan JBL, Miles DH, Leleti MR, Park T, Soriano F, Handlos B, Jeffrey J, Sharif E, Rosen B, Schindler U, Powers JP, Walters MJ. CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; New York, New York; abstract No. A162.

View Poster

April 14-18, 2018
Pharmacokinetic-Pharmacodynamic relationship for AB928, a dual antagonist of the A2aR and A2bR adenosine receptors. Seitz L, Ashok D, Leleti M, Powers J, Rosen B, Miles D, Sharif E, Jin L, Park A, Young S, Soriano F, Rieger A, Karakunnel J, Walters MJ. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 3769.

View Poster

April 14-18, 2018
Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control. Walters MJ, Piovesan D, Tan JBL, DiRenzo D, Yin F, Miles D, Leleti M, Park T, Soriano F, Sharif E, Schindler U and Powers JP. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 5556.

View Poster

April 14-18, 2018
Preclinical characterization of GLS-010 (AB122), a fully human clinical-stage anti-PD-1 antibody. Tan JBL, Chen C, Chen K, Li G, Li J, Liu J, Singh H, Wang G, Yang B, Zhang K, Zhao X, Zheng Y. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 4561.

View Poster

April 14-18, 2018
CD73 inhibitors (CD73i) reverse the AMP/adenosine-mediated impairment of immune effector cell activation by Immune Checkpoint Inhibitors (ICI). Becker A, Narasappa, N, Yin F, Zhang K, Park T, Kalisiak J, Lawson K, Jeffrey J, Powers JP, Schindler U, Walters, MJ, Tan JBL. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 710.

View Poster

April 14-18, 2018
Discovery and characterization of AB680, a potent and selective small-molecule CD73 inhibitor for cancer immunotherapy. Lawson KV, Jin L, Jeffrey J, Kalisiak J, Yin F, Zhang K, Chen A, Swinarski D, Walters MJ, Young S, Schindler U, Powers JP. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 4886.

View Poster

March 23-27, 2018
Adenosinergic Axis Provides an Anchor in Multiple Anti-tumor Combination Strategies. Tan JBL, Becker A, Piovesan D, Yin FF, Soriano F, Leleti M, Jeffrey J, Miles D, Powers JP, Schindler U, Walters MJ. Keystone Symposia on Molecular and Cell Biology: Cancer Immunotherapy: Combinations, Montreal, Canada; Abstract No. 3031.

View Poster